CoChat

Optimizing Therapy for Iron Overload in the Myelodysplastic Syndromes: Recent Developments

Leitch, Heather A. · 2011 · Drugs

The DOI matches its Crossref record; 224 of the 224 references it cites were found in a registry or an index.

Abstract

The myelodysplastic syndromes (MDS) are characterized by cytopenias and risk of progression to acute myeloid leukaemia (AML). Most MDS patients eventually require transfusion of red blood cells for anaemia, placing them at risk of transfusional iron overload. In β-thalassaemia major, transfusional iron overload leads to organ dysfunction and death; however, with iron chelation therapy, organ function is improved, and survival improved to near normal and correlated with the degree of compliance with chelation. In lower-risk MDS, several nonrandomized studies suggest an adverse effect of iron overload on survival and that lowering iron with chelation may minimize this impact. Emerging data indicate that chelation may improve organ function, particularly hepatic function, and a minority of patients may have improvement in cell counts and decreased transfusion requirements. While guidelines for MDS generally recommend chelation in selected lower-risk patients, data from nonrandomized trials suggest iron overload may impact adversely on the outcome of higher-risk MDS and stem cell transplantation (SCT). This effect may be due to increased transplant-related mortality, infection and AML progression, and preliminary data suggest that lowering iron may be beneficial in this patient group. Other areas of active and future investigation include optimizing the monitoring of iron overload using imaging such as T2* MRI and measures of labile iron and oxidative stress; correlating new methods of measuring iron to clinical outcomes; clarifying the contribution of different cellular and extracellular iron pools to iron toxicity; optimizing chelation by using agents that access the appropriate iron pools to minimize the relevant clinical consequences in individual patients; and incorporating measures of quality of life and co-morbidities into clinical trials of chelation in MDS. It should be noted that chelation is costly and potentially toxic, and in MDS should be initiated after weighing potential risks and benefits for each patient until more definitive data are available. In this review, data on the impact of iron overload in MDS and SCT are discussed; for example, several noncontrolled studies show inferior survival in patients with iron overload in these clinical settings, including an increase in transplant-related mortality and infection risk. Possible mechanisms of iron toxicity include oxidative stress, which can damage cellular components, and the documented impact of lowering iron on organ function with measures such as iron chelation therapy includes an improvement in elevated liver transaminases. Lowering iron also appears to improve survival in both lower-risk MDS and SCT in nonrandomized studies. Selected aspects of iron metabolism, transport, storage and distribution that may be amenable to future intervention and improved removal of iron from important cellular sites are discussed, as are attempts to quantify quality of life and the importance of co-morbidities in measures to treat MDS, including chelation therapy.

Overview

Integrity signals

Registry

Crossref · 10.2165/11585280-000000000-00000

Cites

224 of 224 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 224 references

Research works printed but not linked: 16

  1. Alessandrino, 2002, Haematologica, 87, 1286
  2. Malcovati, 2006, Haematologica, 91, 1588
  3. Borgna-Pignatti, 2004, Haematologica, 89, 1187
  4. Jaeger, 1992, Beitr Infusionsther, 30, 464
  5. Mathew, 1993, Blood, 81, 1040, 10.1182/blood.V81.4.1040.1040 · doi:10.1182/blood.v81.4.1040.1040
  6. Del Río Garma, 1997, Haematologica, 82, 639
  7. Okabe, 2009, Rinsho Ketsueki, 50, 1626
  8. Smeets, 1996, Am J Hematol, 51, 243, 10.1002/(SICI)1096-8652(199603)51:3<243::AID-AJH12>3.0.CO;2-H · doi:10.1002/(sici)1096-8652(199603)51:3<243::aid-ajh12>3.0.co;2-h
  9. Hann, 1988, Cancer Res, 48, 4168
  10. McKay, 1996, Bone Marrow Transplant, 17, 63
  11. Gattermann, 2005, Hematol Oncol Clin North Am, 19, 18
  12. Mittelman, 2008, Isr Med Assoc J, 10, 374
  13. Borgna-Pignatti, 1998, Haematologica, 83, 788
  14. Franchini, 2004, Blood, 103, 747, 10.1182/blood-2003-10-3373 · doi:10.1182/blood-2003-10-3373
  15. Porter, 1998, Blood, 92, 668a
  16. Yarali, 2006, J Pediatr Hematol Oncol, 28, 11

Cited by

See all 17

Metadata

Authors
Leitch, H. A.
Affiliations
University of British Columbia (CA)
Corresponding author
Leitch, Heather A.
Venue
Drugs
Published
2011-01
Volume
71
Issue
2
Pages
155-177
ISSN
0012-6667 (ISSN-L)
OpenAlex
W2219541779
Cited by
17
References
224
Citations by year
2021: 2 · 2020: 2 · 2018: 1 · 2016: 2 · 2015: 2 · 2014: 3 · 2013: 1 · 2012: 3
FWCI
0.34
Type
journal article
Language
en
Open access
closed
Locations
  • Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
  • Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Keywords
myelodysplastic syndrome, transfusional iron overload, iron chelation therapy, beta-thalassaemia major, stem cell transplantation, non-relapse mortality, oxidative stress, iron toxicity, liver function, T2-weighted MRI, labile plasma iron, iron metabolism, survival outcomes, transfusion requirements, quality of life
MeSH terms
Clinical Trials as Topic, Humans, Iron, Iron Chelating Agents, Models, Biological, Myelodysplastic Syndromes, Quality of Life, Tissue Distribution, Chelation Therapy, Iron Overload, Transfusion Reaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Optimizing Therapy for Iron Overload in the Myelodysplastic Syndromes: Recent Developments. https://app.cochat.ai/papers/10.2165/11585280-000000000-00000
The paper
Leitch, H. A. (2011). Optimizing Therapy for Iron Overload in the Myelodysplastic Syndromes: Recent Developments. Drugs. https://doi.org/10.2165/11585280-000000000-00000

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.